- Home
- FENC vs AGD Comparison
FENC vs AGD Comparison
Compare FENC & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- AGD
- Stock Information
- Founded
- FENC 1996
- AGD 2006
- Country
- FENC United States
- AGD United Kingdom
- Employees
- FENC 32
- AGD N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- AGD Trusts Except Educational Religious and Charitable
- Sector
- FENC Health Care
- AGD Finance
- Exchange
- FENC Nasdaq
- AGD Nasdaq
- Market Cap
- FENC 222.9M
- AGD 263.6M
- IPO Year
- FENC 2001
- AGD N/A
- Fundamental
- Price
- FENC $8.34
- AGD $10.98
- Analyst Decision
- FENC Strong Buy
- AGD
- Analyst Count
- FENC 2
- AGD 0
- Target Price
- FENC $13.00
- AGD N/A
- AVG Volume (30 Days)
- FENC 83.2K
- AGD 61.2K
- Earning Date
- FENC 08-12-2025
- AGD 01-01-0001
- Dividend Yield
- FENC N/A
- AGD 8.13%
- EPS Growth
- FENC N/A
- AGD N/A
- EPS
- FENC N/A
- AGD N/A
- Revenue
- FENC $30,912,000.00
- AGD N/A
- Revenue This Year
- FENC $0.85
- AGD N/A
- Revenue Next Year
- FENC $55.16
- AGD N/A
- P/E Ratio
- FENC N/A
- AGD N/A
- Revenue Growth
- FENC N/A
- AGD N/A
- 52 Week Low
- FENC $3.96
- AGD $8.20
- 52 Week High
- FENC $8.72
- AGD $9.78
- Technical
- Relative Strength Index (RSI)
- FENC 58.31
- AGD 67.81
- Support Level
- FENC $7.53
- AGD $10.34
- Resistance Level
- FENC $8.68
- AGD $10.83
- Average True Range (ATR)
- FENC 0.49
- AGD 0.11
- MACD
- FENC -0.04
- AGD 0.01
- Stochastic Oscillator
- FENC 63.18
- AGD 92.86
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors among others.